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See related editorial by Flannery et al., http://ccforum.com/content/18/5/509We read with interest the editorial by Flannery and col-
leagues [1], who proposed ‘a dose of healthy skepticism’
toward the findings of our Albumin Italian Outcome
Sepsis (ALBIOS) trial [2]. Although we feel uncertain
about where such ‘health’ may come from, we consider a
few extra words necessary. First, the rationale of the
subgroup analysis of 90-day mortality on septic shock
was based on the Kaplan-Meier estimates for 90-day
survivals of the entire study population, which tended to
separate between groups from day 30. Although this
observation was unexpected, it indicates the potential
beneficial effects of ancillary functions of albumin, besides
its oncotic property [3-5]. When patients with shock as
defined in a broader view (with cardiovascular Sequential
Organ Failure Assessment score of 1, 3, or 4; n = 1,303)
were considered, the beneficial effect of albumin on
90-day survival persisted (relative risk (RR) 0.88, 95%
confidence interval (CI) 0.78 to 0.99, P = 0.03) even
after adjustment for clinically relevant variables (RR
0.88, 95% CI 0.78 to 1.00, P = 0.049). Second, we agree
with the authors on the potential biases of an open-
label study. Nonetheless, we believe that the shorter
time to suspension of vasopressors observed in the
albumin as compared with the crystalloid group is a
solid finding, as supported by a higher or equal mean
arterial pressure over the study observed in the former
as compared with the latter group [2]. In conclusion,
the available data suggest not only that albumin may
be a safe alternative to crystalloids in patients with
severe sepsis but that it may be beneficial in those with* Correspondence: pietro.caironi@unimi.it
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article, unless otherwise stated.shock [6]. Further studies are warranted to confirm
this hypothesis.
Abbreviations
Cl: Confidence interval; RR: Relative risk.
Competing interests
PC has received lecture honoraria from CSL Behring (King of Prussia, PA,
USA) and Grifols (Barcelona, Spain). LG has received lecture honoraria from
CSL Behring, Grifols, Kedrion (Barga, Italy), and Baxter (Deerfield, IL, USA).
Published: 23 September 2014
References
1. Flannery AH, Kane SP, Coz-Yataco AO: A word of caution regarding proposed
benefits of albumin from ALBIOS: a dose of healthy skepticism. Crit Care
2014, 18:509.
2. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C,
Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G,
Latini R, Gattinoni L, ALBIOS Study Investigators: Albumin replacement
in patients with severe sepsis or septic shock. N Engl J Med 2014,
370:1412–1421.
3. Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and
therapeutic potential. Hepatology 2005, 41:1211–1219.
4. Caironi P, Gattinoni L: The clinical use of albumin: the point of view of a
specialist in intensive care. Blood Transfus 2009, 7:259–267.
5. O’Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J,
Karra E, Winstanley A, Alazawi W, Garcia-Martinez R, Cordoba J, Nicolaou A,
Gilroy DW: Immunosuppression in acutely decompensated cirrhosis is
mediated by prostaglandin E2. Nat Med 2014, 20:518–523.
6. Caironi P, Tognoni G, Gattinoni L: Albumin replacement in severe sepsis
or septic shock. N Engl J Med 2014, 371:84.
doi:10.1186/s13054-014-0510-4
Cite this article as: Caironi and Gattinoni: Proposed benefits of albumin
from the ALBIOS trial: a dose of insane belief. Critical Care 2014 18:510.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
